Diag Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Diag Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	$876K	Buy	+12,266	New	+$1.18M	1%	31

Other funds holding NBIX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Diag Capital Management's NBIX Position: Q4 2018 in Review

Diag Capital Management opened a new position in Neurocrine Biosciences (NBIX) in Q4 2018: 12,266 shares worth $876K. The stake represents 1% of the portfolio and ranks #31 among its holdings.

331 funds tracked by Wall St. Rank hold NBIX as of Q4 2018.

Diag Capital Management held 12,266 shares of Neurocrine Biosciences worth $876K as of Q4 2018.
Neurocrine Biosciences was a new Diag Capital Management position in Q4 2018.
Neurocrine Biosciences made up 1% of Diag Capital Management's portfolio in Q4 2018, its #31 holding.
331 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2018.

Based on Diag Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.